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DObjective: The present study was designed to compare stented porcine and bovine pericardial valves used for
pulmonary valve replacement to better define valve performance and postoperative quality of life.
Methods: A retrospective review of all patients who underwent pulmonary valve replacement with a stented
bioprosthesis from 1992 to 2008 was conducted. The medical records, imaging results, and quality of life ques-
tionnaires were analyzed. Differences in reintervention by valve type were determined using Cox proportional
hazards models, controlling for subject age.
Results:A total of 170 consecutive pulmonary valve replacements (73 stented porcine, group 1; 97 bovine peri-
cardial, group 2) were reviewed. No significant differences were seen in patient age or implanted valve size
between the groups. Surgical mortality was 1.2%. The median follow-up was 48.2 months and was longer
for group 2. No significant difference was seen in the risk of reintervention by valve type (hazard ratio, 0.64;
95% confidence interval, 0.18-2.34; P¼ .51). After 39 months of follow-up, pulmonary stenosis and pulmonary
insufficiency that was moderate or worse were more common in patients who had undergone pulmonary valve
replacement at younger than 15 years (pulmonary stenosis, 30.9% vs 10.0%,P¼ .003; pulmonary insufficiency,
46.2% vs 3.8%, P<.001), regardless of valve type. All patients performed well mentally and physically on the
quality of life surveys.
Conclusions: The present large series of stented bioprosthetic pulmonary valve replacements has demonstrated
good results, particularly in adults, at intermediate follow-up. Freedom from reintervention was similar for the
porcine and pericardial valves, and our finding did not clearly demonstrate the superiority of 1 type of valve.
However, the stented bioprosthetic valves were less durable in younger patients. (J Thorac Cardiovasc Surg
2013;146:1461-6)The pulmonary valve is the least commonly replaced car-
diac valve, but it can require replacement either at primary
repair of a congenital cardiac defect or at reoperation. The
options for pulmonary valve replacement (PVR) include
mechanical, homograft, or surgically constructed polytetra-
fluoroethylene valves and xenograft biological valves.1-5
Despite small series showing favorable results,2,6
mechanical valves are typically not used in the pulmonary
position because of the increased risk of thrombosis.
Catheter-delivered stent valves have also recently been
used for PVR.7 Based on observations from our practice
and a review of the published data,1-7 stented
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The Journal of Thoracic and Carvalve substitute for older children and adults. They have
become the valve substitute of choice at our institution in
absence of the need for complex reconstruction of the
right ventricular outflow tract.
However, biological valves are susceptible to degenera-
tion, and patients might require 1 or more reoperations.
Although several previous studies5,8-10 have examined the
results of bioprosthetic PVR with various prosthetic valves,
only 1 other large series of PVR patients comparing the
performance of the available stented bioprostheses has been
published.5 The present study was designed to compare the
outcomes and patient quality of life after PVR using a bovine
pericardial or stented porcine bioprosthetic valve. These data
will also help to provide a standardwithwhich to compare the
results of percutaneously placed pulmonary stent valves,
which have recently been introduced to clinical practice.
METHODS
We identified all patients who had undergone stented bioprosthetic PVR
at Duke University Medical Center from 1992 to 2008. Each patient
received either a bovine pericardial (Perimount; Carpentier-Edwards,
Edwards Lifesciences, Irvine, Calif) or stented porcine xenograft (Hancock
II; Medtronic, Minneapolis, Minn, or Biocor or Epic; St. Jude Medical, St.
Paul, Minn) valve. The medical records were reviewed for demographic
and clinical information and all follow-up imaging results. Pulmonary ste-
nosis (PS) and pulmonary insufficiency (PI) were graded using thediovascular Surgery c Volume 146, Number 6 1461
Abbreviations and Acronyms
PI ¼ pulmonary insufficiency
PS ¼ pulmonary stenosis
PVR ¼ pulmonary valve replacement
RV ¼ right ventricular
TOF ¼ tetralogy of Fallot
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Dfollowing numerical scale: 0, none; 1, trace or trivial; 2, mild; 3, moderate;
and 4, severe, according to the findings from the most recent echocardio-
gram. The patients were contacted and asked to complete the short form
health survey questionnaire (36 item, version 2 for adults and 10-item short
form for children) to evaluate their health and quality of life after sur-
gery.11,12 The Duke University institutional review board approved the
present study. Informed consent was waived for the review of medical
records but obtained from patients contacted for the purposes of
completing the questionnaire.
In each patient, PVR was performed during normothermic or mildly
hypothermic cardiopulmonary bypass. The proximal pulmonary artery
was opened through a longitudinal incision. The bioprosthesis was
implanted while the heart was perfused and beating, unless a residual intra-
cardiac shunt was present. In the latter case, a brief period of induced
ventricular fibrillation or cardioplegic arrest was used to repair the defect,
after which the PVR was completed. The pulmonary artery incision was
extended slightly onto the right ventricle or through a previous outflow tract
patch, as needed, to permit implantation of the appropriate-size valve pros-
thesis. An effort was made to implant the largest size prosthetic valve that
would reasonably fit within the outflow tract. The valve was implanted at or
near the orthotopic position with a running polypropylene suture. Once the
valve was implanted, the right ventricular outflow tract was usually aug-
mented with a patch of polytetrafluoroethylene, unless the pulmonary
artery could be closed primarily over the valve. The use of this technique
allowed the implantation of the optimal size valve.
Data collection and statistical analyses conformed to the guidelines for
reporting mortality and morbidity after cardiac valve interventions.13 Cat-
egorical variables are expressed as frequencies and percentages. Continu-
ous variables are expressed as the mean  standard deviation or median
and range. The Wilcoxon rank sum and Fisher exact test, as appropriate,
were used to compare the demographic variables. Differences in reinter-
vention by valve type were determined using Cox proportional hazards
models, controlling for subject age (<15 vs 15 years). Survival analyses
were performed using the Kaplan-Meier actuarial method.RESULTS
Demographics
Atotal of 161 consecutivepatients underwent 170PVRop-
erations with stented bioprostheses (73 porcine valves, group
1; and 97 bovine pericardial valves, group 2; Table 1). No sig-
nificant difference was seen between the 2 groups in either
age at PVR or implanted valve size. Follow-up was longer
for the group 2 patients (61 36 months vs 33 31 months,
P<.001). Themost commonprimary diagnosiswas tetralogy
of Fallot (TOF) followed by pulmonary atresia with or with-
out a ventricular septal defect (Table 2).Valve Function
Follow-up echocardiography was available for 81% of
the patients. On their most recent echocardiograms,1462 The Journal of Thoracic and Cardiovascular Sura greater percentage of group 2 patients had moderate to
severe PS than group 1 patients (27.0% vs 8.2%,
P ¼ .007), but the mean echocardiographic grade of PS
was similar between the 2 groups (P¼ .89). A significantly
greater percentage of group 2 patients had at least moderate
PI compared with the group 1 patients (26.4% vs 13.3%,
P ¼ .083), and the mean echocardiographic grade of PI
was significantly greater in group 2 than in group 1
(P<.001). However, the echocardiographic follow-up dura-
tion was shorter in group 1 than in group 2 (31.7 vs 55.7
months, P<.001).
Age at PVR significantly affected valve performance.
Age younger than 15 years at PVR was associated with
a greater incidence of both PS (P ¼ .003) and PI
(P<.001) at the last follow-up examination (Table 3). Of
the children younger than 15 years of age, 31% had at least
moderate PS and 46.2% had at least moderate PI compared
with 10.0% and 3.8%, respectively, of older patients (Table
3). The median follow-up was 50 months for the younger
group and 34 months for the older group (P ¼ .047).
Freedom From Reintervention
Freedom from reintervention, either catheter or surgical,
for all patients is shown in Figure 1. The percentage of all
valve replacements that were free from reintervention at
1, 5, and 10 years was 99% (142/144), 94% (66/70), and
36% (9/25), respectively. A total 18 total reinterventions
were required in 16 patients, including 6 transcatheter
balloon valvuloplasties and 12 reoperations. All but 1 of
the patients requiring reintervention was younger than
15 years at PVR. The indications for reintervention
included PS in 12, PI in 8, right ventricular (RV) dilatation
in 4, RV dysfunction in 6, tricuspid regurgitation in 2, and
endocarditis in 2. The average interval from PVR to reinter-
vention was 72 months, including 2 early reoperations for
endocarditis at 2 and 6 months. Pulmonary arterioplasty
or stent placement was attempted in 10 of the 18 cases at
reintervention.
Controlling for patient age at surgery, no significant
difference was seen in the risk of reintervention by valve
type (hazard ratio, 0.64; 95% confidence interval, 0.18-
2.34; P ¼ .51; Figure 2). Controlling for both patient age
and valve size (mm) made no differences in the effect of
valve type on the risk of reintervention. Age younger than
15 years at surgery was a significant risk factor for reinter-
vention (hazard ratio, 19.54; 95% confidence interval, 2.56-
149.19; P ¼ .004; Figure 3). Of the patients younger than
15 years old, 65% received a pericardial valve. Controlling
for valve type, age younger than 15 years at surgery was
a risk factor for reintervention (P<.001). Valve durability
was excellent in older patients. In the 1 patient aged 15 years
or older at primary PVR, the indication for repeat PVR was
prosthetic valve endocarditis, not structural valve
deterioration.gery c December 2013
TABLE 1. Demographics
Variable
Porcine valve
(n ¼ 73)
Pericardial valve
(n ¼ 97) P value
Males (n) 48 (65.7%) 58 (59.8%) .42
Age (y) .31
Median 19 16
Range 4-66 0.5-72
Age<15 y (n) 25 (34.3%) 44 (45.4%) .16
Valve size (mm) .77
Median 25 25
Range 21-29 19-29
Follow-up (mo) < .001
Median 24 58
Range 0.03-135 1-181
TABLE 3. Valve function of stented bioprosthetic pulmonary valves
Variable
Age<15 y
(n ¼ 69)
Age 15 y
(n ¼ 101) P value
Moderate or greater PS (%) 30.9 (17/55) 10 (8/80) .003
Moderate or greater PI (%) 46.2 (24/52) 3.8 (3/80) < .001
PI, Pulmonic insufficiency; PS, pulmonic stenosis.
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DSurgical Mortality and Late Death
Two deaths occurred within 30 days of surgery (2/170,
1.2%). A 12-year-old girl with a history of multiple cardiac
operations, including atrioventricular septal defect repair,
mitral valve replacement, and a Ross-Konno procedure, un-
derwent revision of her RV to pulmonary atrial conduit with
a stented bioprosthetic valve and redo mitral valve replace-
ment. She died on postoperative day 1 of cardiac arrest. The
second early death was a 9-year-old girl who had undergone
repair of TOF during infancy. She underwent an apparently
uncomplicated PVR, had an uneventful postoperative
course, and was discharged to home on postoperative day
7. She died on postoperative day 27 of an unknown cause.
Two additional late deaths occurred at 5.6 years and almost
9 years postoperatively.QRS Duration
In addition to PS and PI, a prolonged QRS interval has
been suggested as an indication for PVR in patients with
TOF. Some have suggested that PVR might stabilize or
result in improvement in the QRS duration. Among all
patients with a preoperative QRS interval greater than
150 ms, no significant change was seen in the QRS duration
(168 ms vs 166 ms, P ¼ .49) at a mean follow-up of
43 months after PVR. Only those patients who hadTABLE 2. Principal diagnosis for all patients
Variable Patients, n
Tetralogy of Fallot variants 86 (53.4%)
Pulmonary atresia with or without VSD 24 (14.9%)
Congenital pulmonary stenosis 16 (9.9%)
After Ross procedure 13 (8.1%)
Truncus arteriosus 6 (3.7%)
Transposition of great arteries 5 (3.1%)
Double outlet right ventricle 4 (2.5%)
Pulmonary valve dysplasia 2 (1.2%)
Other 5 (3.1%)
VSD, Ventricular septal defect.
The Journal of Thoracic and Cara preoperative electrocardiogram within 30 days of surgery
and a postoperative electrocardiogram at least 60 days after
surgery were considered (n ¼ 37).Quality of Life
The quality of life after PVR was evaluated using stan-
dardized assessment tools. The rate of return of the quality
of life surveys was relatively low. Survey results were avail-
able for 34 adults and 17 children younger than 15 years old.
Adult patients performed well from both a mental and
a physical health perspective, with no differences compared
with the general population (Figure 4). As a group, they
were not limited in their ability to perform everyday phys-
ical activities. The survey results for the children showed
that they fared just as well as their peers from a psychosocial
standpoint. However, a trend was seen toward lower scores
in the physical health domain (Figure 5).DISCUSSION
It has been reported that PVR, when performed after re-
pair of various congenital heart defects, including TOF, can
normalize the RV dimensions, improve both RV and left
ventricular contractility, decrease the incidence of symp-
tomatic arrhythmias, improve exercise capacity, and reverse
clinical symptoms.5,14-17 The ideal pulmonary valve
substitute has not yet been clearly defined. Compared
with mechanical, homograft, and polytetrafluoroethylene
valves,1-5 stented bioprosthetic valves in the pulmonaryFIGURE 1. Kaplan-Meier actuarial freedom from reintervention in pa-
tients who underwent stented bioprosthetic pulmonary valve replacement.
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FIGURE 2. Comparison of Kaplan-Meier actuarial freedom from reinter-
vention in patients stratified by valve type. No significant difference was
found in overall reintervention rate between groups. HR, Hazard ratio.
FIGURE 4. Graph showing results of 36-item, version 2, short form
health survey completed by adult patients (n ¼ 34). Horizontal line repre-
sents median value for normal population.
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recent reports.5,10,14-17 However, these reports have mostly
been small series, and none have directly compared the
results of the different available types of stented
bioprosthetic valves. We sought to further elucidate this
issue by reporting 1 of the largest PVR series using these
valves.
In our present study, the surgical mortality of PVR with
stented bioprosthetic valves was 1.2%. Only 2 late deaths
occurred. A total of 18 reinterventions were required in
16 patients after mean follow-up of 48 months, suggesting
that PVR with a stented bioprosthetic valve can be consid-
ered a good PVR option. Although previous reports5,10,14-17
of PVR with stented bioprosthetic valves have beenFIGURE 3. Comparison of Kaplan-Meier actuarial freedom from reinter-
vention in patients younger than 15 years and those 15 years old or older at
pulmonary valve replacement. The re-intervention rate was significantly
greater for the younger group. HR, Hazard ratio.
1464 The Journal of Thoracic and Cardiovascular Surpublished, all but 2 included substantially fewer patients
or patients with both stented and nonstented valves, or both.
In the present study, we sought to compare the outcomes
with stented porcine (group 1) and bovine pericardial
(group 2) valves. Although the duration of follow-up for
the group 2 patients was longer than that for the group 1 pa-
tients, the freedom from reintervention was similar for both
groups. The results of our study were not consistent with the
results from other recent studies that suggested that bovine
pericardial valves are more durable than porcine valves
when used for PVR.5,14 One study by Fiore and
colleagues,14 who compared 3 biologic valve types—pul-
monary homograft, bovine pericardial, and porcine—con-
cluded that a stented porcine valve is more prone to
dysfunction than a bovine pericardial valve (9/47 porcine
valves, 19%, vs 1/18 bovine pericardial valves, 5.5%).
Our study did not confirm this finding. An important differ-
ence between the study by Fiore and colleagues14 and our
study was that their study only included 18 patients with
bovine pericardial valves, but our series included a signifi-
cantly larger number of patients in whom both of these pros-
theses were implanted, with a more convincing statistical
outcome. Another more recent study by Lee and col-
leagues,5 who evaluated the durability of 3 bioprosthetic
valve types in the pulmonary position, demonstrated that
no significant difference was present in the freedom from
valve failure and dysfunction between the stented porcineFIGURE 5. Graph showing results of 10-item, short form health survey
for children completed by pediatric patients (n ¼ 17). Horizontal line rep-
resents median value for normal population.
gery c December 2013
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follow-up of 7.3  2.9 years. It is possible that the differ-
ences we observed between the pericardial and porcine
valves were related to the follow-up duration, because the
patients with pericardial valves had a longer follow-up
time in our series but the patients with porcine valves had
a longer follow-up time in the study by Lee and colleagues.5
Moreover, more patients had bovine pericardial valves
(n ¼ 97) in our series than in the study by Lee and col-
leagues5 (n¼ 53). Unlike in our series, Lee and colleagues5
did not document the statistical similarity in patient age and
valve size between stented porcine and bovine pericardial
valves, making it somewhat more difficult to interpret their
results.
Our data suggest that patient age at surgery, not the
stented bioprosthetic valve type, is the principal determi-
nant of valve performance. A recent study of children
undergoing PVR by Zubairi and colleagues,10 also found
that younger age at PVR was a significant risk factor for
late bioprosthetic valve failure. However, their study
included only 87 total patients and only 16 with stented por-
cine valves. The study by Lee and colleagues5 also demon-
strated that freedom from both prosthetic valve failure and
dysfunction at 10 years was 6.2%  4.2% for patients
younger than 10 years and 12.6%  10.8% for patients
older than 10 years (P < .001). Other studies14-18 have
also demonstrated that young age at valve replacement is
associated with an increased risk of prosthetic valve
failure and dysfunction. In the present study, we sought to
clarify this and to separate the effect of valve type from
age. The large number of patients included in our study
allowed for this comparison. When comparing the groups
and controlling for patient age, no difference was found in
reintervention by valve type. In contrast, when controlling
for valve type, age younger than 15 years was a risk
factor for later reintervention. Our data have shown that
the outcomes for PVR in those aged 15 years or older are
excellent, with only 1 patient requiring late reintervention
thus far. Therefore, consideration should be given to the
size of the stented bioprosthesis that can be implanted in
a child. If a larger valve cannot be implanted, it might be
reasonable to consider implanting a valved conduit, such
as a homograft or bovine jugular vein graft. This would
allow for later placement of a percutaneous stent valve.
Satisfactory results have been reported in studies of valve-
in-valve for a failed bioprosthesis in the pulmonary posi-
tion,19,20 although the follow-up duration has been limited
to date.
Importantly, although it might be fairly common current
practice to place oversize stented valves in younger
patients, a recent study by Chen and colleagues21 has called
this practice into question. In their study, a greater indexed
prosthetic valve size was a risk factor for accelerated struc-
tural valve deterioration in smaller patients. Although ourThe Journal of Thoracic and Carstudy did not include an analysis stratified by the indexed
valve size, it is clear that in younger patients, even the
smallest available stented bioprosthetic valves (19 mm)
will be oversize, because a 19-mm pulmonary valve is the
normal valve diameter for a patient with a body surface
area greater than 1 m2. Therefore, our data support the find-
ings of Chen and colleagues,21 and we would agree that
oversizing a stented bioprosthesis in a smaller, younger
patient will not be beneficial.
A prolonged QRS duration has been strongly associated
with RV function and prognosis in patients with TOF and,
in some studies, has been shown to be reduced postopera-
tively after PVR. In 1 recent study,22 a longer postoperative
QRS duration or a failure to shorten the postoperative QRS
duration was significantly associated with an adverse out-
come. Although the electrocardiographic data were limited
in our study, we also found that in patients with a preopera-
tive QRS duration greater than 150 ms, there was no signif-
icant change in QRS duration (168 ms vs 166 ms) at mean
interval of 43 months after surgery. These data support the
concept that PVR might stabilize the QRS duration,
although they do not support the assertion that PVR effec-
tively shortens the QRS duration.
Limited data have been reported regarding the quality of
life assessment for patients with repaired TOF.23 The qual-
ity of life achieved by PVR has been receiving more atten-
tion in the recent published data of aortic valve replacement
with mechanical versus biologic prostheses,24 mitral valve
replacement or repair,25 and tricuspid valve replacement.26
As yet, little or no data are available regarding the quality of
life of patients after PVR. The present study, to our knowl-
edge, is also the largest series documenting the quality of
life of patients after implantation of a stented bioprosthesis
in the pulmonary valve position. Although the survey return
was suboptimal, quality of life after PVR was measured in
both children and adults in our study and showed results
very similar to those observed in the general population
from both a mental and a physical health perspective. There
might have been a slight trend toward lower physical health
scores in the younger children surveyed, perhaps reflecting
a pediatric population that is more ill than the adults. Over-
all, however, these data suggest that PVRwith a stented bio-
prosthetic valve results in a satisfactory subjective result
from the patient’s perspective.
In conclusion, the present series of a large number of
stented bioprosthetic pulmonary valves indicates that these
valves provide a durable pulmonary valve substitute and
good quality of life, with most patients free from significant
PS or PI at intermediate follow-up. Freedom from reinter-
vention was similar for porcine and pericardial valves,
and the present large study did not clearly demonstrate
the superiority of 1 valve type. The greater overall reinter-
vention rate and amount of PS and PI in the pericardial
group might have reflected the longer follow-up time.diovascular Surgery c Volume 146, Number 6 1465
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increased PS, PI, and reintervention. Valve performance
was excellent in patients aged 15 years or older at PVR.
Valve dysfunction in older patients is more likely to be
due to stenosis, which might be amenable to catheter inter-
vention in place of reoperation. In older adolescents and
adult patients undergoing PVR, stented bioprosthetic valves
should be considered a durable option. In smaller children,
other options should be considered. These data also provide
a useful standard by which to compare stent-mounted
valves in the future.
The present study was limited by its retrospective, single-
center design. Follow-up data were not available for all
patients who underwent PVR and the follow-up duration
differed between the valve types. The choice of biopros-
thetic valve was at the discretion of the surgeon. To truly
determine a difference between stented pericardial and por-
cine valves, a randomized multicenter trial would likely be
required. Also, no preoperative quality of life surveys for
comparison and no standard criteria for reintervention
were available.References
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